Company news

Rein Therapeutics, Inc. news in 2020

Rein Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

November 11, 2020

Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium

October 23, 2020

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

October 11, 2020

Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

September 20, 2020

Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

August 4, 2020

Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August

August 2, 2020

Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924

August 2, 2020

Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares

June 9, 2020

Aileron Therapeutics Announces Pricing of Public Offering of Common Stock

June 3, 2020

Aileron Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2020

Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer

May 31, 2020

Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent

May 26, 2020

Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 10, 2020

Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020

April 21, 2020

Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

March 29, 2020

Decks in 2020